Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression

Overview

Journal Contrast Media Mol Imaging

Specialty Radiology

Date 2022 Aug 15

PMID 35965619

Authors

Na Li

Xiaojie Zhang

Yinsong Zhang

Fang Yang

Fengju Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the significance of PD-1 customization and autoimmune T-cell therapy for advanced colorectal cancer with high MSI expression.

Methods: One hundred and eight patients with advanced colorectal cancer with high MSI expression admitted to our hospital between August 2019 and January 2022 were divided into control and study groups, and PD-1 customization and autoimmune T-cell therapy were administered to the two groups, respectively. Trends in immune indexes, PD-1 exposure, and survival rates were studied in both groups.

Results: The treatment efficiency of the study group was 90.74%, which was higher than that of the control group (61.11%) ( < 0. 05); after treatment, the presence of CDl07a, perforin, and GranB cells was significantly higher in both groups compared with that before treatment, but the expression of PD-1 was more pronounced in the study group ( < 0. 05); that is, the expression of PD-1 in peripheral T lymphocytes in the study group compared with that of the control group was higher in patients with grade III-IV, and peripheral T lymphocytes were also higher in patients with grade III-IV compared with patients with grade I-II ( < 0. 05).

Conclusion: PD-1 customization combined with autoimmune T-cell therapy is a novel therapeutic modality that can substantially improve.

References

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

Affolter A, Kern J, Bieback K, Scherl C, Rotter N, Lammert A . Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). Int J Oncol. 2022; 61(1). PMC: 9183766. DOI: 10.3892/ijo.2022.5378. View

Li H, Yang C, Cheng H, Huang S, Zheng Y . CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. J Cancer. 2021; 12(6):1804-1814. PMC: 7890323. DOI: 10.7150/jca.50509. View

Bruno V, Corrado G, Baci D, Chiofalo B, Carosi M, Ronchetti L . Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal-Maternal Interface. Front Oncol. 2020; 10:156. PMC: 7080858. DOI: 10.3389/fonc.2020.00156. View

Huang X, Tang T, Zhang G, Hong Z, Xu J, Yadav D . Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ Precis Oncol. 2020; 4(1):29. PMC: 7666137. DOI: 10.1038/s41698-020-00136-1. View

Yang W, Lei C, Song S, Jing W, Jin C, Gong S . Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. Cancer Cell Int. 2021; 21(1):589. PMC: 8565029. DOI: 10.1186/s12935-021-02299-8. View

Reichert Z, Urrutia J, Alumkal J . Microsatellite Instability as an Emerging Biomarker for Checkpoint Inhibitor Response in Advanced Prostate Cancer. JAMA Oncol. 2018; 5(4):478-479. DOI: 10.1001/jamaoncol.2018.5789. View

Le Louedec F, Leenhardt F, Marin C, Chatelut E, Evrard A, Ciccolini J . Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. Vaccines (Basel). 2020; 8(4). PMC: 7712135. DOI: 10.3390/vaccines8040632. View

Pao W, Ooi C, Birzele F, Ruefli-Brasse A, Cannarile M, Reis B . Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. Cancer Discov. 2018; 8(4):395-402. DOI: 10.1158/2159-8290.CD-17-1320. View

10.

Golkaram M, Salmans M, Kaplan S, Vijayaraghavan R, Martins M, Khan N . HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. NPJ Genom Med. 2021; 6(1):13. PMC: 7884730. DOI: 10.1038/s41525-021-00177-w. View

11.

Santarpia M, Aguilar A, Chaib I, Cardona A, Fancelli S, Laguia F . Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies. Cancers (Basel). 2020; 12(6). PMC: 7352732. DOI: 10.3390/cancers12061475. View

12.

Ajina A, Maher J . Synergistic combination of oncolytic virotherapy with CAR T-cell therapy. Prog Mol Biol Transl Sci. 2019; 164:217-292. DOI: 10.1016/bs.pmbts.2019.06.015. View

13.

Granier C, Gey A, Roncelin S, WEISS L, Paillaud E, Tartour E . Immunotherapy in older patients with cancer. Biomed J. 2020; 44(3):260-271. PMC: 8358190. DOI: 10.1016/j.bj.2020.07.009. View

14.

Guven D, Sahin T, Erul E, Kilickap S, Gambichler T, Aksoy S . The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022; 14(11). PMC: 9179577. DOI: 10.3390/cancers14112675. View

15.

Merritt C, Ong G, Church S, Barker K, Danaher P, Geiss G . Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020; 38(5):586-599. DOI: 10.1038/s41587-020-0472-9. View

16.

Chen Y, Li Y, Guan Y, Huang Y, Lin J, Chen L . Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors. Mol Oncol. 2020; 14(9):2096-2110. PMC: 7463346. DOI: 10.1002/1878-0261.12739. View

17.

Sorrentino C, DAntonio L, Fieni C, Ciummo S, Di Carlo E . Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Front Immunol. 2022; 12:778329. PMC: 8716410. DOI: 10.3389/fimmu.2021.778329. View

18.

Ahlmanner F, Sundstrom P, Akeus P, Eklof J, Borjesson L, Gustavsson B . CD39 regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function. Oncotarget. 2019; 9(97):36993-37007. PMC: 6319332. DOI: 10.18632/oncotarget.26435. View

19.

Bashir B, Flickinger J, Snook A . Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers. Immunotherapy. 2021; 13(7):561-564. DOI: 10.2217/imt-2021-0012. View

20.

Chabanon R, Rouanne M, Lord C, Soria J, Pasero P, Postel-Vinay S . Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer. 2021; 21(11):701-717. DOI: 10.1038/s41568-021-00386-6. View